cd13  (R&D Systems)

Journal: bioRxiv

Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

doi: 10.64898/2026.02.28.708735

Figure Lengend Snippet: a. Representative survey IHC images of SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes, Cd13-positive immune and stromal cells within the lesion core, and 5HT-positive descending serotonergic tract fibers. b. Gfap intensity plots for partial SCI mice stratified by subgroup. c. Quantification of total Gfap via an area under the curve (AUC) calculation of Gfap intensity from 500µm rostral to 500µm caudal of the lesion epicenter showing a subgroup dependent increase in total Gfap. ***p value < 0.0001, **p value < 0.002, One-way ANOVA with Tukey multiple comparison test. d. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. e. Cd13 intensity plots for partial SCI mice stratified by subgroup. f. Quantification of total Cd13 at SCI lesions at 3 and 14 days after SCI stratified by subgroup. *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data g. Quantification of SCI lesion size at 3 and 14 days after SCI stratified by subgroup. **p value < 0.002, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test on 14d data. Gfap and Cd13 intensity plots show mean as darken lines and s.e.m as shaded area. All graphs are mean ± s.e.m.

Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).

Techniques: Comparison

Journal: bioRxiv

Article Title: Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

doi: 10.64898/2026.02.28.708735

Figure Lengend Snippet: a. Mean Open field (OF) locomotion scores for the saline and coacervate treated SCI mice over two weeks. **p value < 0.005, *p value < 0.05, One-way ANOVA with Tukey multiple comparison test. b. Grid walk (GW) test performance for the saline and coacervate treated SCI mice over two weeks, **p value < 0.0001, *p value < 0.02, One-way ANOVA with Tukey multiple comparison test. c. Correlation analysis of OF and GW scores for carrier injected SCI mice, with the behavioral tests showing strong positive correlation (r=0.86), p-value <0.0001, t-test for Pearson’s linear correlation. d. Pie charts indicating the AFS subgroup distribution across the saline and coacervate injected SCI mice. e. Mean OF, GW and combined assessment PMP values for the AFS designation separated by carrier injection type. f. Confusion matrix showing the percentage of mice displaying Class 1, 2 and 3 type recovery from the three AFS subgroups based on the combined evaluation of OF and GW testing results. g. Representative survey IHC images of carrier treated SCI lesions from the three AFS defined subgroups at 14 days after partial crush injury showing Gfap-positive astrocytes and Cd13-positive immune and stromal cells. h. Quantification of SCI lesion size at 14 days after SCI stratified by subgroup and carrier injection. *p value < 0.05, Two-way ANOVA with Tukey multiple comparison test. i. Quantification of extent of astrocyte bridging at SCI lesions stratified by subgroup and carrier injection., *p value < 0.02, Two-way ANOVA with Tukey multiple comparison test.

Article Snippet: The following primary antibodies were used in this study: anti-Rat Gfap (Invitrogen, 13–0300, 1:1000); anti-Guinea Pig Gfap (Synaptic Systems, 173 308, 1:500); anti-Goat Cd13 (R&D systems, AF2335, 1:500), anti-Rabbit 5-HT (Serotonin) (Immunostar, #20080, 1:1000); anti- Rat MBP (Sigma, MAB386, 1:500).

Techniques: Saline, Comparison, Injection